ClinicalTrials.gg

Program

ATM Inhibitor SYH2051

Also written as “SYH2051 tablets” and “SYH2051”.

Its studies are mostly in Breast Neoplasms · Head and Neck Neoplasms, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since Jan 1, 20253 company-led studies, 3 open or runningNext primary completion: Jun 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group33 open or runningphase 2since Jan 1, 2025Aug 14, 2023Jun 15, 2027phase 2 · NCT06775236

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 14, 2023First study: phase 1 study in Head and Neck NeoplasmsFirst studyNCT06011291 · 73 planned · China
  2. Jan 1, 2025Phase 2 study in Breast NeoplasmsNCT06775236 · 410 planned
  3. Oct 27, 2026Phase 2 study in Advanced Solid TumorsNCT07911579 · 154 planned · China

Ahead

  1. Jun 15, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06775236
  2. Dec 30, 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07911579

TargetBeta

ATM →read by rule
“An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, ”NCIt, by rule

Other programs on ATM

ProgramCompanyFurthest phaseStudies
AZD1390AstraZenecaphase 13
TQB3117Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07911579Advanced Solid Tumors · China2Not yet recruitingDec 30, 2028154
NCT06775236Breast Neoplasms2Not yet recruitingJun 15, 2027410
NCT06011291Head and Neck Neoplasms · China1RecruitingDec 31, 202473

How it is read

Names in the registry

  • “SYH2051 tablets”, 2 entries
  • “SYH2051”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.